In 2002, a landmark study by Coiffier et al. demonstrated that rituximab plus CHOP (R-CHOP) significantly improved overall survival compared to CHOP alone in elderly patients with DLBCL [6]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.